Whalesbook
Kwality Pharmaceuticals saw its share price jump to a new 52-week high on Wednesday following the announcement of strong financial results for the fourth quarter of FY26 and a declared dividend.
The stock reached ₹2,206.55 per share on the BSE, an increase of over 10%. This rise was fueled by the company's Q4FY26 performance, which included its highest-ever quarterly revenue of ₹157.11 crore, marking a 35.8% year-on-year growth from ₹115.67 crore in the same period last year. Investors also reacted positively to the declaration of a ₹2 per equity share dividend for FY26.
Full-Year Performance Boosts Confidence
For the full fiscal year FY26, Kwality Pharmaceuticals reported consolidated revenue of ₹503 crore, a 36% increase from ₹370 crore in FY25. The company's EBITDA margin improved to 24%, up from 22% in FY25. This improvement stems from a better product mix, increased contributions from regulated markets, operating leverage, and growth in registration-led businesses in regions like Mexico and Colombia.
Profitability Sees Significant Growth
Profitability significantly outpaced revenue growth. Profit After Tax (PAT) for FY26 reached ₹67.34 crore, a nearly 69% increase from ₹39.80 crore in FY25. PAT margins expanded by 260 basis points to 13.4% in FY26 from 10.8% in FY25. The company attributes this to enhanced operational efficiencies, better realisations, and strict cost controls.
Outlook for FY27 and Beyond
Kwality Pharmaceuticals reaffirmed its FY27 guidance, projecting ₹650 crore in revenue and ₹100 crore in PAT. The management suggested potential upside to these targets, contingent on the pace of approvals, registrations, and commercialization in international markets. The company's goal is to double its revenue within the next three years, aiming for ₹1,000 crore in topline revenue by FY29, supported by a strong product pipeline and an expanding regulated market presence.